John F. Greden, MD | Psychiatrist.com

Original Research

Utility of Combinatorial Pharmacogenomics in Depression

October 31, 2019

This study sought to ascertain the extent that pharmacogenetic testing can inform treatment decisions among patients with treatment-resistant depression whose medications are subject to gene-drug interactions—read the article to...

Michael E. Thase, Sagar V. Parikh, Anthony J. Rothschild, et al

Consensus Statement

Electroconvulsive Therapy Device Classification: Response to FDA Advisory Panel Hearing and Recommendations

January 15, 2013

Richard Weiner, Sarah H. Lisanby, Mustafa M. Husain, et al

Consensus Statement

Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development: A Consensus Statement

August 16, 2010

Roger E. Meyer, Carl Salzman, Eric A. Youngstrom, et al

Consensus Statement

Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development: A Brief Report

July 13, 2010

Roger E. Meyer, Carl Salzman, Eric A. Youngstrom, et al

Educational Activity

Treating Depression and Pain

June 18, 2009

John F. Greden

Academic Highlights

Depression and Pain.

December 31, 2008

John H. Greist, John F. Greden, James W. Jefferson, et al

Article

Physical Symptoms of Depression: Unmet Needs

April 1, 2003

John F. Greden

Article

Unmet Need: What Justifies the Search for a New Antidepressant?

February 1, 2002

John F. Greden

Article

The Burden of Recurrent Depression: Causes, Consequences, and Future Prospects

January 8, 2001

John F. Greden

Article

The Burden of Disease for Treatment-Resistant Depression

January 2, 2001

John F. Greden